Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVLO Evelo Biosciences	$0.00	$0.00	$0.00 ▼ $0.00	$4K	0.92	8,471 shs	3,832 shs
HOOK HOOKIPA Pharma	$0.90 -1.2%	$0.90	$0.72 ▼ $4.32	$10.91M	1.04	104,188 shs	7,236 shs
IDYA IDEAYA Biosciences	$28.51 +5.3%	$25.34	$13.45 ▼ $32.67	$2.50B	0.14	1.16 million shs	975,078 shs
OGI Organigram Global	$1.96 +3.1%	$1.71	$0.85 ▼ $2.08	$262.64M	1.48	743,558 shs	633,168 shs
TRVN Trevena	$0.01	$0.16	$0.00 ▼ $2.45	$12K	0.63	2,072 shs	240 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVLO Evelo Biosciences	0.00%	-60.00%	-60.00%	-60.00%	+100.00%
HOOK HOOKIPA Pharma	-3.62%	+1.00%	-2.41%	-20.53%	-75.51%
IDYA IDEAYA Biosciences	+1.12%	+0.56%	+10.00%	+22.21%	-11.16%
OGI Organigram Global	-1.04%	-3.06%	+14.46%	+30.14%	+7.34%
TRVN Trevena	0.00%	0.00%	-95.20%	-98.71%	-99.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVLO Evelo Biosciences	$0.00	$0.00	$0.00 ▼ $0.00	$4K	0.92	8,471 shs	3,832 shs
HOOK HOOKIPA Pharma	$0.90 -1.2%	$0.90	$0.72 ▼ $4.32	$10.91M	1.04	104,188 shs	7,236 shs
IDYA IDEAYA Biosciences	$28.51 +5.3%	$25.34	$13.45 ▼ $32.67	$2.50B	0.14	1.16 million shs	975,078 shs
OGI Organigram Global	$1.96 +3.1%	$1.71	$0.85 ▼ $2.08	$262.64M	1.48	743,558 shs	633,168 shs
TRVN Trevena	$0.01	$0.16	$0.00 ▼ $2.45	$12K	0.63	2,072 shs	240 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVLO Evelo Biosciences	0.00%	-60.00%	-60.00%	-60.00%	+100.00%
HOOK HOOKIPA Pharma	-3.62%	+1.00%	-2.41%	-20.53%	-75.51%
IDYA IDEAYA Biosciences	+1.12%	+0.56%	+10.00%	+22.21%	-11.16%
OGI Organigram Global	-1.04%	-3.06%	+14.46%	+30.14%	+7.34%
TRVN Trevena	0.00%	0.00%	-95.20%	-98.71%	-99.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EVLO Evelo Biosciences	0.00	N/A	N/A	N/A
HOOK HOOKIPA Pharma	2.33	Hold	$4.50	402.74% Upside
IDYA IDEAYA Biosciences	2.72	Moderate Buy	$43.36	52.08% Upside
OGI Organigram Global	1.00	Sell	N/A	N/A
TRVN Trevena	2.00	Hold	$5.00	41,566.67% Upside

Current Analyst Ratings Breakdown

Latest OGI, EVLO, HOOK, IDYA, and TRVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2025	IDYA IDEAYA Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/8/2025	OGI Organigram Global	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
9/27/2025	IDYA IDEAYA Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/27/2025	OGI Organigram Global	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
9/18/2025	IDYA IDEAYA Biosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$50.00
9/12/2025	IDYA IDEAYA Biosciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$43.00 ➝ $44.00
9/9/2025	IDYA IDEAYA Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/9/2025	IDYA IDEAYA Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $38.00
9/9/2025	IDYA IDEAYA Biosciences	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$45.00
9/9/2025	IDYA IDEAYA Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/8/2025	IDYA IDEAYA Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Outperform	$36.00

(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EVLO Evelo Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
HOOK HOOKIPA Pharma	$9.35M	1.17	N/A	N/A	$4.25 per share	0.21
IDYA IDEAYA Biosciences	$7M	356.95	N/A	N/A	$12.25 per share	2.33
OGI Organigram Global	$117.47M	2.24	N/A	N/A	$2.07 per share	0.95
TRVN Trevena	$443K	0.03	N/A	N/A	($11.07) per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EVLO Evelo Biosciences	-$114.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	11/24/2025 (Estimated)
HOOK HOOKIPA Pharma	-$43.50M	-$4.73	N/A	N/A	N/A	-785.66%	-120.09%	-77.14%	11/12/2025 (Estimated)
IDYA IDEAYA Biosciences	-$274.48M	-$3.79	N/A	N/A	N/A	N/A	-31.42%	-29.45%	11/3/2025 (Estimated)
OGI Organigram Global	-$33.39M	$0.05	39.11	N/A	N/A	2.86%	-8.19%	-5.79%	12/17/2025 (Estimated)
TRVN Trevena	-$40.29M	-$47.04	N/A	N/A	N/A	N/A	N/A	-119.55%	11/5/2025 (Estimated)

Latest OGI, EVLO, HOOK, IDYA, and TRVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2025	Q3 2025	IDYA IDEAYA Biosciences	-$0.12	N/A	N/A	N/A	$59.98 million	N/A
8/13/2025	Q3 2025	OGI Organigram Global	-$0.01	-$0.03	-$0.02	-$0.03	$68.04 million	$50.49 million
8/5/2025	Q2 2025	IDYA IDEAYA Biosciences	-$0.85	-$0.88	-$0.03	-$0.88	$3.48 million	$6.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EVLO Evelo Biosciences	N/A	N/A	N/A	N/A	N/A
HOOK HOOKIPA Pharma	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
OGI Organigram Global	N/A	N/A	N/A	N/A	N/A
TRVN Trevena	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EVLO Evelo Biosciences	N/A	N/A	N/A
HOOK HOOKIPA Pharma	N/A	3.61	3.61
IDYA IDEAYA Biosciences	N/A	12.39	12.39
OGI Organigram Global	N/A	2.59	1.42
TRVN Trevena	N/A	2.42	2.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EVLO Evelo Biosciences	0.31%
HOOK HOOKIPA Pharma	63.88%
IDYA IDEAYA Biosciences	98.29%
OGI Organigram Global	34.63%
TRVN Trevena	13.56%

Insider Ownership

Company	Insider Ownership
EVLO Evelo Biosciences	1.02%
HOOK HOOKIPA Pharma	3.30%
IDYA IDEAYA Biosciences	2.50%
OGI Organigram Global	0.09%
TRVN Trevena	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EVLO Evelo Biosciences	120	18.98 million	18.79 million	No Data
HOOK HOOKIPA Pharma	160	12.19 million	11.79 million	Optionable
IDYA IDEAYA Biosciences	80	87.64 million	85.45 million	Optionable
OGI Organigram Global	860	134.34 million	134.22 million	Optionable
TRVN Trevena	40	959,000	841,000	Optionable

OGI, EVLO, HOOK, IDYA, and TRVN Headlines

Recent News About These Companies

Softball: Conrad Weiser’s Alex Trevena earns statewide player of the year award; 5 other Berks players honored

July 8, 2025 | msn.com

Trevena, Inc. (TRVN) - Yahoo Finance

June 29, 2025 | finance.yahoo.com

Trevena Enters Securities Exchange Agreement with Investor

May 15, 2025 | tipranks.com

Berks sports roundup: Alex Trevena helps Conrad Weiser to 8-5 softball win

April 11, 2025 | readingeagle.comR

Vanessa Hudgens and Oliver Trevena Appear at Expo West for Caliwater

March 9, 2025 | msn.com

JMP Securities downgrades Trevena (TRVN) to a Hold

December 27, 2024 | markets.businessinsider.com

‘Plane’ Actor Oliver Trevena Signs With Untitled Entertainment

December 16, 2024 | yahoo.com

Lyme Regis town councillor John Trevena stand down

December 11, 2024 | bridportnews.co.ukB

Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

December 10, 2024 | zacks.com

Trevena appoints new financial chief

November 29, 2024 | investing.com

Trevena Appoints Katrine Sutton as New CFO

November 27, 2024 | tipranks.com

HC Wainwright & Co. Downgrades Trevena (TRVN)

November 16, 2024 | msn.com

Trevena, Inc. Navigates Financial Challenges and Strategic Changes

November 9, 2024 | msn.com

Chester County biopharm firm's latest layoffs impact its C-suite

November 7, 2024 | bizjournals.com

Trevena teeters in dangerous territory, terminating CEO and other execs amid strategic review

November 7, 2024 | fiercebiotech.comF

Trevena Reports Third Quarter 2024 Results and Provides Business Update

November 7, 2024 | globenewswire.com

Why Trevena (TRVN) Stock Is Down 43% Today

October 8, 2024 | msn.com

Trevena, Inc. Faces Delisting from Nasdaq

October 6, 2024 | msn.com

Trevena Announces Receipt of Nasdaq Delisting Notification

October 4, 2024 | globenewswire.com

Learn to Evaluate (TRVN) using the Charts

September 16, 2024 | news.stocktradersdaily.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OGI, EVLO, HOOK, IDYA, and TRVN Company Descriptions

Evelo Biosciences NASDAQ:EVLO

$0.0002 0.00 (0.00%)

As of 10/14/2025 03:00 PM Eastern

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

HOOKIPA Pharma NASDAQ:HOOK

$0.90 -0.01 (-1.20%)

As of 12:35 PM Eastern

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

IDEAYA Biosciences NASDAQ:IDYA

$28.51 +1.44 (+5.32%)

As of 03:28 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Organigram Global NASDAQ:OGI

$1.96 +0.06 (+3.11%)

As of 03:27 PM Eastern

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

Trevena NASDAQ:TRVN

$0.01 0.00 (0.00%)

As of 12:14 PM Eastern

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OGI, EVLO, HOOK, IDYA, and TRVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OGI, EVLO, HOOK, IDYA, and TRVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OGI, EVLO, HOOK, IDYA, and TRVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OGI, EVLO, HOOK, IDYA, and TRVN Company Descriptions

Evelo Biosciences NASDAQ:EVLO

HOOKIPA Pharma NASDAQ:HOOK

IDEAYA Biosciences NASDAQ:IDYA

Organigram Global NASDAQ:OGI

Trevena NASDAQ:TRVN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools